LifeVantage (NASDAQ:LFVN) Coverage Initiated by Analysts at Craig Hallum

Craig Hallum assumed coverage on shares of LifeVantage (NASDAQ:LFVN - Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating and a $35.00 price objective on the stock.

Separately, Lake Street Capital began coverage on LifeVantage in a report on Thursday, December 19th. They issued a "buy" rating and a $26.00 target price on the stock.

LifeVantage Stock Performance

Shares of NASDAQ:LFVN traded up $2.62 during midday trading on Tuesday, hitting $25.62. 570,372 shares of the stock were exchanged, compared to its average volume of 291,271. The business's 50-day moving average price is $16.07 and its 200 day moving average price is $11.77. LifeVantage has a 12 month low of $5.22 and a 12 month high of $27.38. The stock has a market capitalization of $320.89 million, a price-to-earnings ratio of 80.07 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. The company had revenue of $47.21 million for the quarter. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%.

LifeVantage Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were given a dividend of $0.04 per share. The ex-dividend date was Monday, December 2nd. This represents a $0.16 annualized dividend and a dividend yield of 0.62%. LifeVantage's payout ratio is 50.00%.

Institutional Investors Weigh In On LifeVantage

A number of hedge funds have recently added to or reduced their stakes in the business. Capital Management Corp VA acquired a new stake in LifeVantage in the 3rd quarter valued at $5,073,000. HighTower Advisors LLC acquired a new stake in shares of LifeVantage in the 3rd quarter worth about $638,000. Renaissance Technologies LLC lifted its position in LifeVantage by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 855,118 shares of the company's stock valued at $5,490,000 after acquiring an additional 17,300 shares in the last quarter. Barclays PLC boosted its stake in LifeVantage by 38.2% during the 3rd quarter. Barclays PLC now owns 41,966 shares of the company's stock valued at $507,000 after purchasing an additional 11,608 shares during the last quarter. Finally, Ritholtz Wealth Management increased its holdings in LifeVantage by 62.0% during the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company's stock worth $346,000 after purchasing an additional 10,974 shares in the last quarter. 35.32% of the stock is currently owned by institutional investors.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.